Acute Myeloid Leukemia (AML) Therapeutics Market Size Value

Newark, August 29, 2022 (GLOBE NEWSWIRE) — According to a report published by The Brainy Insights, the global market for acute myeloid leukemia (AML) treatments is expected to grow from $1,043.52 million in 2021 to $2,588. .23 million by 2030. at a CAGR of 10.62% over the forecast period 2022-2030.

Download the report (PDF over 235 pages with information, graphs, tables and figures) at: https://www.thebrainyinsights.com/enquiry/sample-request/12868

Acute myeloid leukemia is a type of cancer that initially affects the bone marrow and then the blood cells. If not treated properly, it can progress rapidly. Acute myeloid leukemia usually begins with cells that are not fully developed. After being affected, these cells lose their potential to carry out their daily activities. This type of leukemia is difficult to treat; thus, one or another therapeutic is always in clinical trials. The therapeutics of acute myeloid leukemia can be started in the patient after a specific period of time from diagnosis. Clinical trials of patients with acute myeloid leukemia focus on the effectiveness of drugs and treatment methods in eliminating the need for cancer cells. Some of the patients diagnosed with acute myeloid leukemia experience problems related to blood circulation. Chemotherapy is used in this case to reduce the total number of affected cells in the blood.
Therapeutics of acute myeloid leukemia (AML) is constantly evolving to deal with the increase in cases of blood cancer. The number of people who have acute myeloid leukemia has increased in the last decade. Also, people are more prone to bone marrow cancer as they age. Its prevalence has increased rapidly among women and men aged 75 to 84 years. Cases of acute myeloid leukemia are increasing even in infants; nearly one-sixth of children who have leukemia are diagnosed with acute myeloid leukemia. Demographic evolution and living standards have led to the adoption of unhealthy habits. Therefore, the increasing preference for advanced therapies for early diagnosis and treatment of acute myeloid leukemia is one of the lucrative opportunities for market growth. Patients are more inclined to use such therapies to increase their chances of survival. The constant technological evolution of therapeutics has led to a shorter response time and greater chances of recovery. However, the high cost of the equipment used in the therapeutics and the possible side effects is an important restriction in the market. In addition, non-uniform reimbursement scenarios and strict product approval regulations are some of the challenges for the acute myeloid leukemia (AML) therapeutic market.

See also  Gender parity and socioeconomic improvement

For More Information On The Analysis Of This Report, Please Visit: https://www.thebrainyinsights.com/report/acute-myeloid-leukemia-aml-therapeutics-market-12868

Key players operating in the global acute myeloid leukemia (AML) therapeutics market are Cephalon Inc., Novartis AG, Celgene Corporation, Pfizer Inc., Eisai Co. Ltd, Bristol Myers Squibb, Eli Lilly and Company, Sunesis Pharmaceuticals Danaher Corporation, Otsuka Holdings Co. Ltd., Genzyme Corporation, Takeda Pharmaceuticals, Ambit Biosciences Corporation, among others. To enhance their market position in the global acute myeloid leukemia (AML) therapeutics market, key players are now focusing on adopting strategies such as product innovations, mergers and acquisitions, recent developments, joint ventures, collaborations, and partnerships.

• In May 2021, two major players, the Straumann Group and Western Dental & Orthodontics collaborated to expand access to dental implants. Straumann Group had agreed to deliver high quality dental implants, abutments and crowns.

The myelomonocytic segment had the highest share of around 38.84% and a market value of USD 405.30 million in 2021.

The disease type segment is divided into myelomonocytic, myeloblastic, and promyelocytic. The myelomonocytic segment had the highest share of around 38.84% and a market value of USD 405.30 million in 2021. Myelomonocytic is a complex condition with heterogeneous symptoms of myelodysplastic and myeloproliferative. Patients diagnosed with myelomonocytic have dysplastic cells present in their bone marrow.

The chemotherapy segment had the highest share of around 42.67% and a market value of USD 445.26 million in 2021.

The treatment type segment is divided into radiation therapy, stem cell transplant, targeted therapy, and chemotherapy. Chemotherapy also includes antimetabolites, hormone therapy, cytarabine, alkylating agents, tyrosine kinase inhibitors, anthracycline drugs, and others. The chemotherapy segment had the highest share of around 42.67% and a market value of USD 445.26 million in 2021. Chemotherapy is one of the most effective drug treatments that uses powerful chemicals, which are used to kill cancer cells in the patient’s body. Cytarabine is approved by the FDA and is recommended for injection.

See also  AFMC auditor flaunts "can do" attitude

The VCD regime segment had the highest share of around 37.90% and a market value of USD 395.49 million in 2021.

The rate segment is divided into VCD rate, DC rate and AVD rate. The VCD regimen segment had the highest share of around 37.90% and a market value of $395.49 million in 2021. VCD regimens are used to treat myelomonocytic and myeloblastic. It is administered in injectable form under the advice of doctors and health professionals. The favorable toxicity profile of VCD makes it suitable for use in the treatment of acute myeloid leukemia.

The hospital segment had the highest share of around 46.32% and a market value of USD 483.35 million in 2021.

The end-user segment is divided into hospitals, ambulatory care centers, clinics, and others. The hospital segment had the highest share of around 46.32% and a market value of USD 483.35 million in 2021. The demand for acute myeloid leukemia treatments in hospitals is increasing due to the increasing demand from the patient population. Hospitals generally have more resources than other end users, which attracts a patient base. Hospital professionals provide full-time treatment care to patients diagnosed with leukemia.

Interested in acquiring the data? Check here at: https://www.thebrainyinsights.com/enquiry/buying-inquiry/12868

Regional Segment Analysis of Acute Myeloid Leukemia (AML) Therapeutics Market

• North America (USA, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America)
• Middle East and Africa (UAE, South Africa, Rest of MEA)

Among all regions, the North America region emerged as the largest market for the global acute myeloid leukemia (AML) treatment market, with a market share of 39.19% in 2021. Treatment for The acute myeloid leukemia (AML) region has intense research and development, technological innovations, and mergers and acquisitions of players dedicated to acute myeloid leukemia (AML) therapeutics. The local population in North America is experiencing an increased prevalence of many types of leukemia. The United States accounted for the largest country-level participation in 2021. The development of reimbursement strategies and favorable demographic trends have led to awareness among the patient population in North American countries. Each year, North American countries invest considerable funds to research and develop treatments for acute myeloid leukemia (AML). As a result of these advances and an increased focus on healthcare technology, the market for acute myeloid leukemia (AML) treatments in the region has exploded in recent years.

See also  Preparing for perimenopause: instructions

About the report:

The global Acute Myeloid Leukemia (AML) Therapeutics market is analyzed on the basis of value (Million US Dollars). All segments have been analyzed at the global, national and country levels. The study includes the analysis of more than 30 countries for each segment. The report offers an in-depth analysis of driving factors, opportunities, restraints, and challenges to gain key insights into the market. The study includes Porter’s five forces model, attractiveness analysis, raw material analysis, supply and demand analysis, competitor position grid analysis, and marketing and distribution channel analysis.

Do you have any questions? Ask our experts: https://www.thebrainyinsights.com/enquiry/speak-to-analyst/12868

About smart ideas:

Brainy Insights is a market research company, whose goal is to provide actionable insights through data analysis to businesses to improve their business acumen. We have a robust forecasting and estimating model to meet customers’ goals of high-quality production in a short period of time. We provide custom (customer-specific) and syndicated reports. Our repository of syndicated reports is diverse across all categories and subcategories across all domains. Our customized solutions are designed to meet the requirements of clients, whether they are looking to expand or planning to launch a new product in the global market.

Contact Us

Avinash D.
Head of Business Development
Phone: +1-315-215-1633
Email: [email protected]
Web: www.thebrainyinsights.com

Acute Myeloid Leukemia (AML) Therapeutics Market Size Value Brainy Insights Pvt Ltd